Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin, China.
Department of Electrical diagnose, The Fourth Hospital of Jilin University, Changchun, Jilin, China.
IUBMB Life. 2018 Jul;70(7):625-632. doi: 10.1002/iub.1753. Epub 2018 May 18.
In this work, we explored the aberrant expression pattern, clinical association, and functional regulations of microRNA-1270 (miR-1270) in osteosarcoma. Among in vitro osteosarcoma cell lines and in situ tissues of osteosarcoma patients, quantitative real time-PCR was used to examine their endogenous miR-1270 expression. Clinical correlation between endogenous miR-1270 expression and clinicopathological features of osteosarcoma patients, as well as cancer patients' overall survival, was statistically examined. MiR-1270 was downregulated in 143B and MG-63 cells by lentiviral transduction. The mechanistic effects of miR-1270 downregulation on osteosarcoma in vitro proliferation and migration, as well as in vivo tumorigenesis, were further examined. MiR-1270 was aberrantly upregulated in both in vitro osteosarcoma cell lines and in situ human tumors. Statistical analysis demonstrated endogenous miR-1270 was associated with poor clinical outcomes and shorter overall survival of osteosarcoma patients. Lentivirus-induced miR-1270 downregulation inhibited cancer in vitro proliferation and migration, as well as in vivo tumorigenesis. Aberrant upregulation miR-1270 may be a prognostic biomarker for osteosarcoma patients with poor clinical outcomes and shorter survival. Inhibition of miR-1270 may also be a potential therapeutic target for anticancer treatment in osteosarcoma. © 2018 IUBMB Life, 70(7):625-632, 2018.
在这项工作中,我们探讨了微小 RNA-1270(miR-1270)在骨肉瘤中的异常表达模式、临床相关性和功能调控。通过定量实时 PCR 检测体外骨肉瘤细胞系和骨肉瘤患者原位组织中的内源性 miR-1270 表达。统计分析内源性 miR-1270 表达与骨肉瘤患者临床病理特征及癌症患者总生存期的临床相关性。通过慢病毒转导使 143B 和 MG-63 细胞中的 miR-1270 下调。进一步检测 miR-1270 下调对骨肉瘤体外增殖和迁移以及体内肿瘤发生的机制作用。miR-1270 在体外骨肉瘤细胞系和原位人肿瘤中均异常上调。统计分析表明,内源性 miR-1270 与骨肉瘤患者的不良临床结局和较短的总生存期相关。慢病毒诱导的 miR-1270 下调抑制了癌症的体外增殖和迁移以及体内肿瘤发生。miR-1270 的异常上调可能是骨肉瘤患者预后不良和生存期较短的预后生物标志物。抑制 miR-1270 也可能是骨肉瘤抗癌治疗的潜在治疗靶点。© 2018 IUBMB Life,70(7):625-632,2018。